It was showed that compared to the respective normal tissues, SHMT2 was highly expressed in adrenal cancer, bladder cancer, breast cancer, liver cancer, colorectal cancer, lung cancer, ovary cancer, pancreatic cancer, prostatic cancer, stomach cancer, testis cancer, skin cancer, thyroid cancer, uterus cancer, renal cancer as well as acute myelogenous leukemia (AML). This evidence concerns the gene SHMT2 and urinary bladder carcinoma.